Drug intelligence / Profile preview

dexamethasone + olanzapine + ondansetron

Development stage: Phase 3
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a three-drug antiemetic combination regimen used for the prevention of chemotherapy-induced nausea and vomiting (CINV), particularly in patients receiving highly emetogenic chemotherapy (HEC) such as cisplatin-based regimens. The combination has shown effectiveness in controlling both acute (0-24 hours) and delayed (24-120 hours) phases of CINV. Studies have demonstrated that 5 mg olanzapine combined with ondansetron and dexamethasone is effective at reducing CINV and may also have beneficial effects on anxiety and depression in cancer patients undergoing chemotherapy.

Targets

DRD2 (Dopamine D2 Receptor)GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on dexamethasone + olanzapine + ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + olanzapine + ondansetron.